Amylyx Pharmaceuticals Inc (AMLX)
$26.02 -$0.20 (-0.76%) 4:40 AM 11/22/2026
NASDAQ | $USD | Drug Manufacturers - Specialty & GenericStock Data
-
Market Cap
$3.35B -
Day's Range
$25.52 - $26.40 -
Volume
1,559,797 -
52 Week Low / High
$10.83 - $41.14 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
Analyst ratings: Buy 11, Hold 1, Sell 0.
Company News
-
LUCIDITY met its prespecified primary endpoint; avexitide reduced the composite Level 2/3 hypoglycemic event rate by 55% compared to placebo (p=0.000003) Avexitide showed consistent, highly statistically significant reductions across all prespecified, multiplicity-controlled secondary even...
-
Amylyx Pharmaceuticals (AMLX) Stock Looks Pricey After Positive Phase 3 Results — Nov 7, 2026
Amylyx Pharmaceuticals has delivered a very strong year to date share price gain. With that kind of move on the board, the key issue for you now is whether the stock price still lines up with the company's book value. A year to date return of 158.3% puts real pressure on the question of wh...
-
Amylyx Pharmaceuticals (AMLX) Posts Positive Phase 3 Data, Is The 30% Discount Justified? — Nov 7, 2026
Amylyx Pharmaceuticals (AMLX) has drawn fresh attention after reporting a third quarter net loss of US$45.49 million, alongside positive Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia and plans for an FDA filing. Amylyx Pharmaceuticals has seen momentum build through 20...
Portfolio
Comprised of 1 portfolios



